1、该刊只有国际刊号。

2、投稿方式：在线投稿。

3、官网网址：

https://mednexus.org/journal/jco

4、投稿系统：

https://www.editorialmanager.com/jcardiooncol/default2.aspx

5、中华医学期刊全文数据库：

https://www.yiigle.com/Journal/JCO

6、官网电话：0411-83635963-2139

7、官网邮箱：joco@cmaph.org

8、出刊日期：季刊，一年出版四期。

2026年1月12日星期一

Instructions for Authors

【官网信息】

The

Editorial Office is pleased to answer any questions you may have about

preparing your manuscript in accordance with our guidelines.

Email: joco@cmaph.org

AIMS AND SCOPE

Journal Aims:

Promote

Multidisciplinary Collaboration: To highlight and advance the role of

multidisciplinary teams (MDTs) in the diagnosis, treatment, and

management of cardio-oncology patients, fostering a holistic and

patient-centered approach to care.

Disseminate

Cutting-Edge Research: To publish high-quality, innovative research

that spans the entire spectrum of cardio-oncology, from basic and

translational science to clinical studies and outcomes research.

Educate

Healthcare Professionals: To provide comprehensive knowledge that

support the continuous professional development of all members of the

MDT, including cardiologists, oncologists, radiologists, surgeons,

nurses, and allied health professionals.

Address

Global Health Disparities: To promote research and practices that

address health disparities in cardio-oncology care, ensuring equitable

access to the latest advancements in diagnosis, treatment, and

prevention worldwide.

Promote

Patient-Centered Care: To emphasize the importance of involving

patients and their families in treatment decisions and care planning,

incorporating patient perspectives and experiences into the journal’s

content.

Disseminate

knowledge through a diverse range of content formats, including

original research articles, reviews, commentaries, patient case studies,

interactive multimedia content, sharing best practices tailored to

different healthcare professionals within the Cardio-Oncology MDT.

Journal Scope:

The

Journal of Cardio-Oncology welcomes submissions that cover a broad

range of topics within the field, including but not limited to:

Clinical

Research: Studies on the diagnosis, treatment, and management of

cardiovascular complications in cancer patients, including clinical

trials, case reports, and observational studies.

Basic

and Translational Science: Research on the underlying mechanisms of

cardiotoxicity, biomarkers, and susceptibility to cardiovascular injury

caused by cancer therapies.

Multidisciplinary

Team Approaches: Articles that showcase the benefits and challenges of

MDTs in cardio-oncology, including best practices, protocols, and case

studies, including clinical practice guidelines and clinical consensus

statements.

Innovative

Therapies and Technologies: Research on new therapeutic strategies,

emerging technologies, and interventions that improve the care of

cardio-oncology patients (such as AI and precision medicine).

Patient

and Family Perspectives: Narratives and studies that highlight the

experiences and outcomes of patients and their families, emphasizing the

importance of patient-centered care (including psychosocial aspects of

cancer and cardiovascular disease, including patient advocacy and

support strategies).

Health

Policy and Advocacy: Discussions on healthcare policies, organizational

strategies, and advocacy efforts that support the integration and

effectiveness of MDTs in cardio-oncology.

Global

Health: Research addressing the global disparities in cardio-oncology

care, with a focus on innovative solutions for low- and middle-income

countries.

Educational

Resources: Educational articles, reviews, and multimedia content aimed

at the continuous education and training of MDT members in the latest

advancements and best practices in cardio-oncology.

ONLINE SUBMISSION

First-time Users

Please

click the Register button at

https://www.editorialmanager.com/jcardiooncol/default.aspx. Upon

successful registration, you will be sent an email providing your

username and password. Save this information for future reference.

Note:

If you have received an email from us with an assigned username and

password, or if you are a repeat user, do not register again. Once you

have an assigned username and password, you do not have to re-register.

Authors

Please

click the Login button from the menu at the top of the page and login

to the system as an author. Submit your manuscript according to the

author instructions. You will be able to track the process of your

manuscript through the system.

JOURNAL POLICIES

Duplicate Publication

Manuscripts

are reviewed for possible publication with the understanding that they

are being submitted only to the Journal of Cardio-Oncology and have not

been published, simultaneously submitted, or already accepted for

publication elsewhere. The Editorial team may subject any manuscript

submitted for consideration of publication in the Journal of

Cardio-Oncology to plagiarism-detection software.

This

does not preclude consideration of a manuscript that has been rejected

by another journal or a complete report that follows publication of

preliminary findings elsewhere, usually in the form of an abstract.

Copies of any possibly duplicate published material should be submitted

with the manuscript under consideration, with a statement in the cover

letter as to why the manuscript currently being submitted is not a

duplicate publication.

Disclosure of Conflicts

Authors

must state all possible conflicts of interest in the manuscript,

including financial, consultant, institutional and other relationships

that might lead to bias or a conflict of interest. If there is no

conflict of interest, this should also be explicitly stated as none

declared. All sources of funding should be acknowledged in the

manuscript.

All

relevant conflicts of interest and sources of funding should be

included on the title page of the manuscript with the heading "Conflicts

of Interest” and “Source of Funding".

For

example: “Conflicts of Interest: A has received honoraria from Company

Z. B is currently receiving a grant (#12345) from Organization Y, and is

on the speaker's bureau for Organization X - the CME organizers for

Company A. For the remaining authors none were declared.”

“Source of Funding”: list all the grant supports/funders for the study.

A

financial disclosure section is part of the submission process and must

be completed by each author at first revision. This information is for

review by the Editors but will be published if relevant to the content

of the accepted manuscript.

The

primary purpose of the disclosure section is to determine whether

authors have received any commercial financial support that could create

a conflict of interest. In addition to monetary interests, a potential

for conflict of interest can exist whether or not an individual believes

that a relationship (such as dual commitments, competing interests, or

competing loyalties) affects his or her scientific judgment. Please

review ICMJE Uniform Requirements for Manuscripts Submitted to

Biomedical Journals at the following link:

http://www.icmje.org/conflicts-of-interest.

Studies in Humans and Animals

If

the work involves the use of human subjects, the author should ensure

that the work described has been carried out in accordance with The Code

of Ethics of the World Medical Association (Declaration of Helsinki)

for experiments involving humans. The manuscript should be in line with

the Recommendations for the Conduct, Reporting, Editing and Publication

of Scholarly Work in Medical Journals and aim for the inclusion of

representative human populations (sex, age and ethnicity) as per those

recommendations. The terms sex and gender should be used correctly.

Authors

should include a statement in the manuscript that informed consent was

obtained for experimentation with human subjects. The privacy rights of

human subjects must always be observed.

Authors

describing studies involving animals must have consulted the ‘Animal

Research: Reporting In Vivo Experiments’ (ARRIVE) 2.0 guidelines,

developed by the NC3Rs to improve standards of reporting, ensuring that

the data from animal experiments can be fully scrutinized and utilized.

Articles reporting in vivo experiments must adhere to the ARRIVE

Essential 10 checklist as a minimum, and we encourage authors to use the

full ARRIVE 2.0 checklist. The relevant information outlined in these

guidelines should be included in the appropriate section of the article.

Ethics

When

reporting studies on human subjects, author should indicate whether the

procedures followed were in accordance with the Declaration of Helsinki

(https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/).

For prospective studies involving human participants, authors are

expected to mention about approval of regional/national/institutional or

independent ethics committee or review board, obtaining informed

consent from adult research participants and obtaining assent for

children aged over 7 years participating in the trial. The age beyond

which assent would be required could vary as per regional and/or

national guidelines. Ensure confidentiality of subjects by desisting

from mentioning participants’ names, initials or hospital numbers,

especially in illustrative material. When reporting experiments on

animals, indicate whether the institution’s or a national research

council’s guide for, or any national law on the care and use of

laboratory animals was followed.

Evidence

for approval by a local ethics committee (for both human as well as

animal studies) must be supplied by the authors on demand. Animal

experimental procedures should be as humane as possible, and the details

of anesthetics and analgesics used should be clearly stated. The

ethical standards of experiments must be in accordance with the

guidelines provided by the ARRIVE and World Medical Association

Declaration of Helsinki on Ethical Principles for Medical Research

Involving experimental animals and human beings, respectively. The

journal will not consider any paper which is ethically unacceptable. A

statement on ethics committee permission and ethical practices must be

included in all research articles under the “Methods” section.

We

reserve the right to decline publication of a paper even after it has

been accepted if it becomes apparent that there are serious problems

with the scientific content or violations of our publishing policies.

Protection of Patients’ Rights to Privacy

Identifying

information should not be published in written descriptions,

photographs, sonograms, CT scans, etc., and pedigrees unless the

information is essential for scientific purposes and the patient (or

parent or guardian, wherever applicable) gives written informed consent

for publication. Authors should remove patients’ names from figures

unless they have obtained written informed consent from the patients.

The journal abides by ICMJE guidelines: (1) Authors, not the journals

nor the publisher, need to have the patient consent form before the

publication related to patient privacy and have the form properly

archived by the author. (2) If the publication includes some facial

images that make the patients identifiable, a statement about the

patient’s consent needs to be present in the manuscript.

......

更多详见：

https://mednexus.org/journal/jco/authors/instructions